ProMIS Neurosciences Inc (PMN)

[noretreat]

From today's release: "Although both BAN2401 and aducanumab have shown encouraging phase 2 clinical results, the greater selectivity and avoidance of plaque binding with PMN310 may confer significant advantages in the clinic supporting PMN310 as potential 'best in class' therapy."

----------------------------------

ProMIS Neurosciences Oligomer Selective Antibody Therapeutic for Alzheimer's Disease, PMN310, Shows Potential for Improved Safety Profile in Direct Comparison to Other Amyloid Beta-Directed...
HUGIN 6:30 AM ET 8/21/2018

Lack of PMN310 binding to amyloid deposits in Alzheimer's brain tissue may eliminate dose-limiting brain swelling seen with BAN2401 and aducanumab

TORONTO and CAMBRIDGE, Mass., Aug. 21, 2018 (GLOBE NEWSWIRE) -- ProMIS
Neurosciences, Inc. , a biotechnology company focused on
the discovery and development of antibody therapeutics selectively targeting
toxic oligomers implicated in the development of neurodegenerative diseases,
today announced that its lead antibody candidate for Alzheimer's disease (AD),
PMN310, showed no binding to amyloid beta (AB) plaque in AD brain samples in
stark contrast to BAN2401 and aducanumab which both displayed robust AB plaque
reactivity. These findings extend the results ProMIS announced in January 2018,
showing greater selectivity of PMN310 for AB oligomers compared to aducanumab.
Binding of therapeutic antibodies to AB deposits in brain tissue, in particular
blood vessels, is believed to underlie the development of ARIA (amyloid-related
imaging abnormalities; brain swelling and microhemorrhages) in treated AD
patients.

Commenting on these results, ProMIS President and CEO, Elliot Goldstein, MD,
stated: "PMN310 was designed to selectively target soluble toxic AB oligomers,
now widely believed to be a root cause of AD. By not targeting AB plaque,
especially in and around blood vessels in the brain, we anticipate PMN310 may
not be associated with the dose-limiting brain swelling seen with plaque-binding
antibody therapeutics like BAN2401 and aducanumab. Confirmation of such an
improved safety profile in clinical trials would allow for administration of
higher doses to AD patients, thereby potentially leading to greater therapeutic
potency of PMN310."

The binding profile of PMN310 in human AD brain tissues was directly compared to
that of BAN2401 and aducanumab in a preclinical study using the technique of
immunohistochemistry (IHC). Results of the study showed binding of BAN2401 and
aducanumab to AB plaque throughout the brain and in association with blood
vessels. Conversely, binding of PMN310 to AB plaque was not observed in any
region of the AD brain tissues.

BAN2401 (Esai/Biogen) and aducanumab (Biogen) appear to target both AB plaque
and soluble AB oligomers. Recent clinical trials with both BAN2401 and
aducanumab, reporting a dose-related response curve (i.e., higher doses enabling
greater efficacy) support the targeting of AB oligomers for the treatment of AD
and at the same time indicate that treatment with antibodies also targeting AB
plaque is associated with dose-limiting brain swelling in a significant
percentage of AD patients. We have shown in multiple preclinical studies that
PMN310 has the advantage of selectively targeting toxic AB oligomers, with no
"off-target" binding to AB plaque, potentially allowing for the safe
administration of higher effective doses of PMN310 compared to BAN2401 or
aducanumab.

According to Dr. Goldstein, "Although both BAN2401 and aducanumab have shown
encouraging phase 2 clinical results, the greater selectivity and avoidance of
plaque binding with PMN310 may confer significant advantages in the clinic
supporting PMN310 as potential 'best in class' therapy."

IHC is the process of selectively imaging antigens (e.g. proteins) in cells of a
tissue section by exploiting the principle of antibodies (such as PMN310,
aducanumab, BAN2401) binding specifically to their antigen targets in biological
tissues. In the study referred to above, IHC was used to assess binding of AB-
directed antibodies to AB plaque in AD brain tissue.

About ProMIS Neurosciences(ARFXF)ProMIS Neurosciences, Inc.(ARFXF) is a development stage biotechnology company focused
on discovering and developing antibody therapeutics selectively targeting toxic
oligomers implicated in the development and progression of neurodegenerative
diseases, in particular Alzheimer's disease (AD), amyotrophic lateral sclerosis
(ALS) and Parkinson's disease (PD). The Company's proprietary target discovery
engine is based on the use of two complementary techniques. The Company applies
its thermodynamic, computational discovery platform-ProMIS(TM) and Collective
Coordinates - to predict novel targets known as Disease Specific Epitopes on the
molecular surface of misfolded proteins. Using this unique precision medicine
approach, the Company is developing novel antibody therapeutics for AD, ALS and
PD. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge,
Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol
PMN, and on the OTCQB Venture Market under the symbol ARFXF.

For further information please consult the Company's website at: www.promisneurosciences.com


Follow us on Twitter
Like us on LinkedIn

For media inquiries, please contact:
Shanti Skiffington
[e-mail]
Tel. [phone]

or Kristen Galfetti
[e-mail]
Tel. [phone]

For Investor Relations please contact:
Alpine Equity AdvisorsNicholas Rigopulos, President
[e-mail]
Tel. [phone]

Dr. Elliot Goldstein
President and Chief Executive Officer, ProMIS Neurosciences Inc.(ARFXF)
Tel. [phone]
[e-mail]

The TSX has not reviewed and does not accept responsibility for the adequacy or
accuracy of this release. This information release contains certain forward-
looking information, including about the timing and completion of the Offering,
the receipt of TSX approval and the expected use of proceeds from the Offering.
Such information involves known and unknown risks, uncertainties and other
factors that may cause actual results, performance or achievements to be
materially different from those implied by statements herein, and therefore
these statements should not be read as guarantees of future performance or
results. All forward-looking statements are based on the Company's current
beliefs as well as assumptions made by and information currently available to it
as well as other factors. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date of this press
release. Due to risks and uncertainties, including the risks and uncertainties
identified by the Company in its public securities filings, actual events may
differ materially from current expectations. The Company disclaims any intention
or obligation to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: ProMIS Neurosciences(ARFXF) via GlobeNewswire